The Cigna Group (NYSE:CI)’s Evernorth division has announced a new deal with Novo Nordisk and Eli Lilly that will limit insured customers’ monthly out-of-pocket expenses for weight-loss drugs Zepbound and Wegovy to $200.

Cigna’s (NYSE:CI) health services arm, Evernorth, has launched a pharmacy benefit program that caps out-of-pocket costs at $200 per month for patients using the weight-loss drugs - Wegovy from Novo Nordisk (NVO) and Eli Lilly’s (NYSE:LLY) Zepbound.

Cigna’s pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers.